Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method
| Autor: | Tomohiro Takenoue, Hirokazu Nagawa, Keiji Matsuda, Tetsuichiro Muto, Joji Kitayama, Kenji Hatano, Takashi Tsuruo, Marcelo Eidi Nita, Shin Fujii |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Oncology
Male medicine.medical_specialty Antimetabolites Antineoplastic Colorectal cancer Gastroenterology Thymidylate synthase Statistics Nonparametric Surgical oncology Internal medicine Carcinoma medicine Humans Survival analysis Proportional Hazards Models Chi-Square Distribution biology business.industry Proportional hazards model Thymidylate Synthase Middle Aged medicine.disease Immunohistochemistry Survival Analysis Treatment Outcome Fluorouracil Colonic Neoplasms biology.protein Surgery Female business medicine.drug |
| Zdroj: | Annals of surgical oncology. 7(3) |
| ISSN: | 1068-9265 |
| Popis: | Thymidylate synthase (TS) is regarded as a parameter of 5-fluorouracil (5-FU) chemosensitivity for colorectal carcinoma. Recent researchers indicate that the chemosensitivity of 5-FU for colorectal carcinoma with low expression of TS is better than tumors with high expression of TS. But the relation between TS expression and overall survival of curatively resected colorectal cancer patients has been less studied.Specimens of curatively resected colon carcinoma from 148 patients were included in this study. TS expression in the tumor was assessed by immunohistochemical staining technique, and the patients were categorized into TS-(+) and TS-(-) groups. First, the relation between TS expression and survival of patients was examined. Next, for each group, we compared survival between the chemotherapy-(+) and the chemotherapy-(-) subgroup.Overall survival was significantly better in the TS-(-) group (n = 107) than in the TS-(+) group (n = 41) (P = .0003). In the TS-(-) group, there was little difference between the chemotherapy-(+) and the chemotherapy-(-) subgroup. In the TS-(+) group, the survival of the chemotherapy-(+) subgroup was significantly better than the chemotherapy-(-) subgroup (P = .0439).TS, itself, may be a prognostic factor for colon carcinoma; and 5-FU adjuvant chemotherapy may be appropriate for colon carcinoma with high expression of TS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink